{"id":"W4395084838","doi":"10.1093/rheumatology/keae163.293","title":"E066 Baseline characteristics of patients initiating ixekizumab, secukinumab or a tumour necrosis factor inhibitor by country in the 24-month Prospective Psoriatic Arthritis Observational Study of Persistence of Treatment - PRO-SPIRIT","year":2024,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; University Health Network","funders":"Medac; Celgene; Teva Pharmaceutical Industries; Gilead Sciences; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; Biogen; GlaxoSmithKline","keywords":"Secukinumab; Medicine; Ixekizumab; Psoriatic arthritis; Observational study; Internal medicine; Arthritis; Persistence (discontinuity); Dermatology; Oncology; Physical therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001161279,0.0003739107,0.0006995898,0.001073924,0.0004757688,0.0009083612,0.0006055835,0.0006605756,0.00315455],"category_scores_gemma":[0.002782254,0.0003810784,0.00111627,0.001772853,0.0003717044,0.0006635727,0.0006116938,0.0008688176,0.0005497613],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004085359,"about_ca_system_score_gemma":0.0004684261,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007056745,"about_ca_topic_score_gemma":0.00653785,"domain_scores_codex":[0.9987287,0.0002874442,0.0002017839,0.0003753784,0.0002309392,0.0001756471],"domain_scores_gemma":[0.9965976,0.0005463464,0.001728774,0.0002633054,0.0002876617,0.0005763154],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0009837523,0.00007792876,0.997561,0.00001698032,0.0002499291,0.0000270241,0.00002949881,0.00007566675,0.0001268392,0.00001782462,0.0003603399,0.0004732874],"study_design_scores_gemma":[0.0001150378,0.0002986664,0.9986155,0.000009465793,0.00006892999,0.000125771,0.0001087035,0.0002385791,0.00003171787,0.00001821717,0.0003607396,0.000008731172],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9882894,0.0002690597,0.0001468333,0.00005880019,0.00001373221,0.00003856207,0.01040565,0.000007776662,0.00077018],"genre_scores_gemma":[0.9915605,0.0000781438,0.0001037906,0.00007473278,0.00001643132,0.00004547086,0.007799825,0.000004072762,0.0003170757],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007056745,"threshold_uncertainty_score":0.01403135,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0429452569140167,"score_gpt":0.2613057523428631,"score_spread":0.2183604954288464,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}